None listed
Conditions
Brief summary
The purpose of this study is to test if a chemical called prochlorperazine (Stemetil) can move the target of a chemotherapy drug called cetuximab to the surface of cancer cells. Who is it for? You may be eligible for this study of you are aged 18 or over and have a squamous cell carcinoma of head and neck which is amenable to biopsy Study details All participants in this study will have a small biopsy of their tumour then an infusion of the study drug (prochlorperazine) through a needle in their arm 60-90 minutes before another biopsy of their tumour. The biopsy sample will be analysed in a laboratory to see the effect of the drug on a receptor on the surface of cancer cells. It is hoped this research will demonstrate that prochlorperazine makes cancer cells more sensitive to the chemotherapy drug cetuximab.
Interventions
Prochlorperazine 0.8mg/kg by intravenous infusion over 20-30 mins; tissue biopsy from tumour areas accessible without surgery occurred prior to start of infusion and 60-90 minutes post-infusion.
Sponsors
University Of Queensland
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Histologically confirmed squamous cell carcinoma of head and neck mucosa Tumour of any stage amenable to biopsy
Exclusion criteria
Eastern Cooperative Oncology Group (ECOG) performance status equal to or greater than 2; On drugs that cause long QTc ; History of prolonged QT interval or prolonged QT interval on baseline ECG; Systolic blood pressure less than 90mmHg and/or diastolic blood pressure < 50 mmHg in two consecutive blood pressure readings within the 1 hour prior to study drug administration; Previous reaction to antipsychotic medications requiring medical intervention; Pregnant or breast feeding Excluded if Parkinson’s disease.
Outcome results
None listed